PMV Pharmaceuticals filings document a clinical-stage precision oncology company focused on small molecule therapies targeting p53. The company’s Form 8-K reports disclose operating results, financial condition updates, Regulation FD materials, and rezatapopt clinical disclosures from the PYNNACLE study in tumors with a TP53 Y220C mutation.
Proxy materials describe annual meeting matters, board composition, stockholder voting procedures, and governance practices. The filing record also identifies PMV’s Nasdaq-listed common stock and includes risk and forward-looking-statement disclosures tied to drug development, regulatory pathways, capital resources, and clinical-stage biotechnology operations.
PMV Pharmaceuticals, Inc. (PMVP) – Form 4 insider transaction
President & CEO David Henry Mack reported a sale of 58,411 common shares on 07/01/2025 at an average price of $1.0645 per share. The sale was executed under Rule S (open-market or private sale) and, according to the filing, was undertaken solely to cover tax obligations arising from the vesting of restricted stock units (Footnote 1).
After the transaction, Mack continues to own 536,133 shares directly. He also has indirect interests of 165,307 shares (Stinson 2021 Irrevocable Trust), 147,915 shares (Mack-Mulligan Revocable Trust) and 56,978 shares (Mack/Mulligan 2020 Irrevocable Descendants’ Trust), bringing his total reported beneficial position to 906,333 shares. No derivative securities were bought or sold, and there were no new options, warrants, or RSU transactions reported.
The sale represents roughly 10.9 % of Mack’s direct holdings and about 6.4 % of his total reported beneficial ownership. Because the disposition was for tax-withholding purposes, it does not necessarily signal a change in sentiment; nevertheless, investors often monitor any CEO share sales for potential insight into insider views of future prospects.